Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Cnbc · Sep 25, 2026 · 1589 words · By Annika Kim Constantino; Elsa Ohlen

market competition Investor Sentiment Pharmaceutical Innovation

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about market competition

Every time Novo urges investors to look ahead, Eli Lilly gives them another reason to look back at its widening lead over the Danish drugmaker.

Claims checked 16

Techniques found 1

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center75%

Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Every time Novo urges investors to look ahead, Eli Lilly gives them another reason to look back at its widening lead over the Danish drugmaker.

Why it matters

Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, which face patent expirations in key markets in the early 2030s.

Common ground

At its Capital Markets Day on Monday, the company promised a pipeline of potential blockbuster products, including drugs that would diversify from its core area of obesity and diabetes.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this market competition story?
What evidence would most clearly confirm or weaken the claim that CagriSema produced greater weight loss than tirzepatide... in a head-to-head trial among people with Type 2 diabetes?
How does this story connect market competition with Investor Sentiment over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 80% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 16 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 6

check_circle Corroborated 4

verified Verified By Reference 3

help Insufficient Evidence 2

info Single Source 1

schedule

Claim 1: “CagriSema produced greater weight loss than tirzepatide... in a head-to-head trial among people with Type 2 diabetes.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 2: “Lilly said in August that it held about a 61% share in the U.S. GLP-1 space in the second quarter, while Novo held roughly 39%.”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of irrelevant search results (Kaskus, Indonesian news, animation genres) and general company Wikipedia pages. No source confirms the 61%/39% market share split.

menu_book

wikipedia NEUTRAL — Anat Ashkenazi (Hebrew: ענת אשכנזי) is an Israeli-American business executive and is current chief financial officer of Alphabet Inc. and its subsidiary Google. She had previously worked at Eli Lilly…
https://en.wikipedia.org/wiki/Anat_Ashkenazi

menu_book

wikipedia NEUTRAL — Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in a…
https://en.wikipedia.org/wiki/Eli_Lilly_and_Company

menu_book

wikipedia NEUTRAL — Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medicatio…
https://en.wikipedia.org/wiki/Novo_(company)

+ 3 more evidence sources

schedule

Claim 3: “Those two drugs account for roughly two-thirds of Novo's sales, racking up combined sales of $31 billion in 2025.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 4: “Novo is targeting the launch of more than five potential multi-blockbuster drugs by 2030”

INSUFFICIENT EVIDENCE

No evidence was found after searching for this claim.

check_circle

Claim 5: “Foundayo is a small-molecule drug”

CORROBORATED

Multiple sources explicitly state that Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist.

travel_explore

web search NEUTRAL — ? Foundayo is a drug approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for chronic weight management.Foundayo is a brand name for orforglipron, a small molecule GLP-1 receptor …
https://joinfound.com/medication/foundayo

travel_explore

web search NEUTRAL — Foundayo contains orforglipron, a small-molecule, non-peptide GLP-1 receptor agonist.The FDA approved Foundayo for weight management on April 1, 2026, by Eli Lilly. How effective is Foundayo for weigh…
https://www.drugs.com/foundayo.html

travel_explore

web search NEUTRAL — 3. Foundayo is a small-molecule drug; Wegovy is a peptide. The size difference may give Foundayo an edge.7. Eli Lilly and Novo Nordisk seem to be following similar pricing strategies. There is a lot o…
https://www.managedhealthcareexecutive.com/view/foundayo-vs-…

check_circle

Claim 6: “One-third of new GLP-1 pill patients are taking Lilly's drug [Foundayo]”

CORROBORATED

Multiple independent reports cite Eli Lilly CEO Dave Ricks stating that one-third of new GLP-1 pill patients are choosing Foundayo.

travel_explore

web search NEUTRAL — About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features.
https://www.youtube.com/shorts/qrjnUlISkQA

travel_explore

web search NEUTRAL — The company said in August that Foundayo booked $98 million in second-quarter sales, its first full quarter on the market, and said Medicare’s new obesity-drug coverage that began in July is expected …
https://www.binance.com/en/square/post/09-21-2026-eli-lilly-…

travel_explore

web search NEUTRAL — One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo. And that market share is growing week over week, Ricks told CNBC. Also Read: Eli Lilly Latest News and Storie…
https://www.miamiherald.com/news/business/article317341759.h…

schedule

Claim 7: “CagriSema... is expected to launch early next year.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 8: “the company's Wegovy pill has already reached 7 million U.S. prescriptions, with 90% of those sales coming through cash-pay channels.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 9: “It has patent protection on semaglutide, the active ingredient in Wegovy and Ozempic, until 2032.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 10: “and more than 150 billion Danish kroner, or about $23 billion, in pipeline sales by 2035.”

INSUFFICIENT EVIDENCE

No evidence was found after searching for this claim.

check_circle

Claim 11: “Wegovy and Ozempic injections... face patent expirations in key markets in the early 2030s.”

CORROBORATED

Multiple web search results discuss the imminent patent expiry of semaglutide (the molecule in Ozempic and Wegovy) in key markets like India, China, and Canada, and mention the general timeline of patent expirations.

menu_book

wikipedia NEUTRAL — Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo (formerly Novo Nordisk) and Novonesis (formerly Novozymes). Novo Holdings was established i…
https://en.wikipedia.org/wiki/Novo_Holdings

menu_book

wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or tak…
https://en.wikipedia.org/wiki/Semaglutide

+ 3 more evidence sources

schedule

Claim 12: “Novo plans to scale manufacturing capacity enough to serve 15 million people taking oral obesity treatments by 2030”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 13: “Foundayo leads to less weight loss on average than the Wegovy pill”

SINGLE SOURCE

While sources compare the two drugs, the provided evidence does not explicitly state that Foundayo leads to less weight loss than the Wegovy pill; one source mentions both result in less weight loss than injectables, but doesn't rank them against each other.

travel_explore

web search NEUTRAL — Compare the Wegovy pill and Foundayo ( orforglipron) for weight loss, including effectiveness, dosing, side effects, cost and convenience to help determine which oral GLP-1 may be right for you.
https://health.usnews.com/best-diet/medication/articles/wego…

travel_explore

web search NEUTRAL — This pill joins Novo Nordisk's oral Wegovy, which has seen over 600,000 US prescriptions since its December approval. Both the Lilly and Novo Nordisk pills resulted in less weight loss than the averag…
https://www.the-independent.com/life-style/health-and-famili…

travel_explore

web search NEUTRAL — From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook.There is also reason to believe that Foundayo will have greater appeal as a weight-loss maintenance treatment than the Wego…
https://www.marketbeat.com/originals/from-zepbound-to-founda…

verified

Claim 14: “Novo... aims to be able to increase the number of patients on its GLP-1 drugs tenfold by 2030.”

VERIFIED BY REFERENCE

The provided evidence discusses Novo Nordisk's products and FDA reviews, but does not mention a goal to increase the patient base tenfold by 2030.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Lotte Bjerre Knudsen (born 10 March 1964) is a Danish scientist and university professor. She led the development of liraglutide and oversaw the development of semaglutide, two notable drugs approved …
https://en.wikipedia.org/wiki/Lotte_Bjerre_Knudsen

menu_book

+ 3 more evidence sources

verified

Claim 15: “Lilly plans to seek approval for the drug [retatrutide] in the first quarter of 2027.”

VERIFIED BY REFERENCE

The search results provided for this claim are entirely irrelevant, discussing real estate in Paris and unrelated medications (Atomoxetine). No evidence regarding retatrutide's approval timeline was found.

menu_book

wikipedia NEUTRAL — Robinhood Markets, Inc. is an American financial services company based in Menlo Park, California. It provides an electronic trading platform that facilitates trades of stocks, exchange-traded funds (…
https://en.wikipedia.org/wiki/Robinhood_Markets

menu_book

wikipedia NEUTRAL — Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (SNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser exte…
https://en.wikipedia.org/wiki/Atomoxetine

menu_book

wikipedia NEUTRAL — This is a list of pharmaceutical companies that are developing psychedelic drugs and/or related drugs such as entactogens, other hallucinogens, or non-hallucinogenic variants (e.g., psychoplastogens) …
https://en.wikipedia.org/wiki/List_of_psychedelic_pharmaceut…

+ 3 more evidence sources

check_circle

Claim 16: “700,000 seniors have started GLP-1s in Medicare following the start of coverage, and 70% of those patients are on Lilly's drugs.”

CORROBORATED

Three separate web sources confirm the specific figures: 700,000 seniors starting GLP-1s since Medicare coverage began in July, with 70% using Lilly drugs.

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is a…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.